Opinion|Videos|July 11, 2024
Evaluating Value of BTK Inhibitors in CLL Treatment
Experts evaluate the value of BTK inhibitors in CLL treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How are payers evaluating the value of BTK inhibitors in the evolving treatment landscape of CLL?
Advertisement
Related to this article
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
Using Complement Inhibitors in GA Comes With Pros and Cons
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5